Advances in 177 Lu-PSMA and 225 Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer.
Sui Wai LingErik de BloisEline HooijmanAstrid A M van der VeldtTessa BrabanderPublished in: Pharmaceutics (2022)
For patients with metastatic castration-resistant prostate cancer (mCRPC), the survival benefit of classic treatment options with chemotherapy and drugs targeting androgen signaling is limited. Therefore, beta and alpha radionuclide therapy (RNT) have emerged as novel treatment options for patients with mCRPC. Radioligands target the prostate-specific membrane antigen (PSMA) epitopes, which are upregulated up to a thousand times more in prostate cancer cells compared to the cells in normal tissues. For this reason, PSMA is an excellent target for both imaging and therapy. Over the past years, many studies have investigated the treatment effects of lutetium-177 labeled PSMA ( 177 Lu-PSMA) and actinium-225 labeled PSMA ( 225 Ac-PSMA) RNT in patients with mCRPC. While promising results have been achieved, this field is still in development. In this review, we have summarized and discussed the clinical data of 177 Lu-PSMA and 225 Ac-PSMA RNT in patients with mCRPC.
Keyphrases
- pet ct
- pet imaging
- positron emission tomography
- squamous cell carcinoma
- gene expression
- stem cells
- machine learning
- radiation therapy
- cell proliferation
- mass spectrometry
- photodynamic therapy
- oxidative stress
- combination therapy
- endoplasmic reticulum stress
- artificial intelligence
- locally advanced
- big data
- cell cycle arrest
- cell therapy
- free survival
- pi k akt